Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
24 Aug 2020
Historique:
received: 17 01 2020
accepted: 11 08 2020
entrez: 25 8 2020
pubmed: 25 8 2020
medline: 15 4 2021
Statut: epublish

Résumé

In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection. The indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using pre-determined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries. A total of 96 indicators were identified from an initial list of 1325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers > 20 mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate. This systematic approach led to the identification of 13 BCSP candidate performance indicators to be further evaluated for their association with BC mortality.

Sections du résumé

BACKGROUND BACKGROUND
In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection.
METHODS METHODS
The indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using pre-determined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries.
RESULTS RESULTS
A total of 96 indicators were identified from an initial list of 1325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers > 20 mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate.
CONCLUSION CONCLUSIONS
This systematic approach led to the identification of 13 BCSP candidate performance indicators to be further evaluated for their association with BC mortality.

Identifiants

pubmed: 32831048
doi: 10.1186/s12885-020-07289-z
pii: 10.1186/s12885-020-07289-z
pmc: PMC7444070
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

795

Subventions

Organisme : European Commission, Joint Research Centre Ispra, Italy
ID : Not applicable

Investigateurs

Mariangela Autelitano (M)
Edoardo Colzani (E)
Jan Daneš (J)
Axel Gräwingholt (A)
Lydia Ioannidou-Mouzaka (L)
Susan Knox (S)
Miranda Langendam (M)
Helen McGarrigle (H)
Elsa Pérez Gómez (E)
Ruben van Engen (R)
Sue Warman (S)
Kenneth Young (K)
Cary van Landsveld-Verhoeven (C)
Donata Lerda (D)
Zuleika Saz-Parkinson (Z)
Elena Parmelli (E)
Annett Janusch-Roi (A)

Références

BMJ. 2016 Jun 28;353:i2016
pubmed: 27353417
Medicine (Baltimore). 2017 Jan;96(3):e5684
pubmed: 28099330
Breast Care (Basel). 2011;6(2):104-109
pubmed: 21673820
Cancer Epidemiol. 2015 Oct;39(5):783-9
pubmed: 26315486
Acta Oncol. 2008;47(8):1618
pubmed: 18759146
J Med Screen. 2012;19 Suppl 1:14-25
pubmed: 22972807
J Med Screen. 2005;12(1):33-7
pubmed: 15814017
Eur J Cancer Prev. 2005 Apr;14(2):107-16
pubmed: 15785314
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Lancet. 2012 Nov 17;380(9855):1778-86
pubmed: 23117178
J Med Screen. 2019 Sep;26(3):120-126
pubmed: 30621498
Breast. 2017 Dec;36:89-95
pubmed: 28988610
Ann Intern Med. 2019 Aug 20;171(4):273-280
pubmed: 31330534
Br J Cancer. 2017 Mar 14;116(6):828-839
pubmed: 28183141
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Curr Oncol. 2016 Apr;23(2):81-90
pubmed: 27122972
J Med Screen. 2012;19 Suppl 1:42-56
pubmed: 22972810
Value Health. 2013 Jun;16(4):647-54
pubmed: 23796300

Auteurs

Sergei Muratov (S)

Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.

Carlos Canelo-Aybar (C)

Iberoamerican Cochrane Center, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau-CIBERESP), Barcelona, Spain.

Jean-Eric Tarride (JE)

Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.

Pablo Alonso-Coello (P)

Iberoamerican Cochrane Center, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau-CIBERESP), Barcelona, Spain.

Nadya Dimitrova (N)

European Commission, Joint Research Centre, Via E. Fermi 2749 - TP 127, I-21027, Ispra, VA, Italy. Nadya.Dimitrova@ec.europa.eu.

Bettina Borisch (B)

Institute of Global Health, University of Geneva, Geneva, Switzerland.

Xavier Castells (X)

IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Stephen W Duffy (SW)

Queen Mary University of London, London, UK.

Patricia Fitzpatrick (P)

National Screening Service, Dublin, Ireland.
UCD School of Public Health, Physiotherapy & Sports Science, Dublin, Ireland.

Markus Follmann (M)

German Cancer Society, Berlin, Germany.

Livia Giordano (L)

CPO-Piedmont - AOU Città della Salute e della Scienza, Torino, Italy.

Solveig Hofvind (S)

Cancer Registry of Norway, Oslo, Norway.

Annette Lebeau (A)

University Medical Center Hamburg-Eppendorf and Private Group Practice for Pathology, Hamburg, Germany.

Cecily Quinn (C)

St. Vincent's University Hospital, Dublin, Ireland.

Alberto Torresin (A)

ASST Grande Ospedale Metropolitano, Milan, Italy.

Claudia Vialli (C)

European Commission, Joint Research Centre, Via E. Fermi 2749 - TP 127, I-21027, Ispra, VA, Italy.

Sabine Siesling (S)

Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands.
University of Twente, Enschede, Netherlands.

Antonio Ponti (A)

CPO-Piedmont - AOU Città della Salute e della Scienza, Torino, Italy.

Paolo Giorgi Rossi (P)

AUSL Reggio Emilia, IRCCS, Reggio Emilia, Italy.

Holger Schünemann (H)

Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.

Lennarth Nyström (L)

Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden.

Mireille Broeders (M)

Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands. Mireille.Broeders@radboudumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH